Biotech Values

[masterlongevity]

MDVN

Interestingly, results of the 1st 6 month Ph 3 symptomatic trial in Mild to moderate AD for Dimebon are due in Jan 2010. If these results are as positive as the russian ph 2 results, it may change the face of AD drug development as dimebon may quickly be part of the SoC placebo arms.